Splenic infarction associated with sorafenib use in a hepatocellular carcinoma patient
Author:
Open Access
- 1 January 2011
- journal article
- case report
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 17 (2) , 267-70
Abstract
Sorafenib, a multitargeted tyrosine kinase inhibitor, has been shown to improve survival in patients with advanced hepatocellular carcinoma (HCC). As the clinical use of sorafenib increases, many adverse effects have been reported, such as hand-foot skin reaction, diarrhea, anorexia, asthenia, alopecia, weight loss, hypertension and arterial thromboembolism. However, there are no prior reports of splenic infarction as an adverse effect of sorafenib. Here, a case of splenic infarction in a patient with HCC who was treated with sorafenib is reported. The patient had no other predisposing factors to explain the splenic infarction except for the administration of sorafenib. The splenic infarction improved after sorafenib was discontinued; however, the HCC progressed.Keywords
This publication has 12 references indexed in Scilit:
- Risk of Arterial Thromboembolic Events With Sunitinib and Sorafenib: A Systematic Review and Meta-Analysis of Clinical TrialsJournal of Clinical Oncology, 2010
- Thrombotic Events in Patients With Cancer Receiving Antiangiogenesis AgentsJournal of Clinical Oncology, 2009
- Sorafenib in Advanced Hepatocellular CarcinomaNew England Journal of Medicine, 2008
- Arterial Thromboembolic Events in Patients with Metastatic Carcinoma Treated with Chemotherapy and BevacizumabJNCI: Journal of the National Cancer Institute, 2007
- Mechanisms of adverse effects of anti-VEGF therapy for cancerBritish Journal of Cancer, 2007
- Oral Antiplatelet Therapy in Cerebrovascular Disease, Coronary Artery Disease, and Peripheral Arterial DiseaseJAMA, 2004
- Platelet-Active Drugs: The Relationships Among Dose, Effectiveness, and Side EffectsChest, 2004
- Bevacizumab, Bleeding, Thrombosis, and WarfarinJournal of Clinical Oncology, 2003
- Polycythemia vera: myths, mechanisms, and managementBlood, 2002
- Signaling mechanisms mediating vascular protective actions of vascular endothelial growth factorAmerican Journal of Physiology-Cell Physiology, 2001